Advertisement

Topics

Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

05:03 EDT 25th September 2016 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 14,000+

Extremely Relevant

Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder

SOUTH SAN FRANCISCO, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that the European Medicines Agency (EMA) granted orphan drug designation for the Company’s allogeneic ...


Can Epstein-Barr Virus Increase Breast Cancer Risk?

Epstein-Barr Virus might increase the risk of breast cancer, according to experiments with cell lines and mouse xenografts that identified a potential mechanism for the suspected link.

Molecular Methods Compared for Quantitative Detection of Epstein-Barr Virus

Quantitative detection of Epstein-Barr virus by real time polymerase chain reaction (PCR) has become standard of care in the management...


Donor epstein-barr serostatus influences GVHD after allo-HSCT

(HealthDay)—Donor Epstein-Barr virus (EBV) serostatus influences incidence of graft-versus-host disease (GVHD) in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT), according to a study published online April 18 in the Journal of Clinical Oncology.

Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell metastasis and invasion by targeting long non-coding RNA LOC553103

Eppstein Barr virus may promote breast cancer development

New research reveals that infection with the Epstein-Barr virus (EBV) may put some women at increased risk for developing breast cancer. The findings, published online in the July issue of the journal EBioMedicine, may have important implications for...

Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas

“Kissing Disease” Virus Promotes Malignant Breast Cancer Development

In our adolescent years, we would often snicker at other kids who were diagnosed with mononucleosis, as it was (and often still is) colloquial referred to as the “kissing disease.” However, in recent years mounting evidence has suggested that infection with Epstein-Barr virus (EBV) has become associated with various forms of cancer—which is certainly no laughing matter. Alarm...

BRIEF-Atara biotherapeutics says European Medicines Agency granted orphan drug designation for allogeneic epstein-barr virus targeted cytotoxic t-lymphocyte product candidate

* European Medicines Agency granted orphan drug designation for allogeneic epstein-barr virus targeted cytotoxic t-lymphocyte product candidate

Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate

SOUTH SAN FRANCISCO, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life threatening diseases that have been underserved by scientific innovation, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) reported ...

Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA)

SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that the EMA has classified the Company’s EBV-CTL product candidate as an Advanced Therapy Medicinal Product (ATMP) that falls within the defini...

Medical News Today: What is Mono and Should I Worry About It?

Learn all about mono, a condition that is often caused by the Epstein-Barr virus. This article looks at the symptoms, causes, treatment, and prevention.

Atara Bio Doses First Patient in Multi-Center Expanded Access Protocol for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) in EBV-Associated Lymphomas and Lymphoproliferative Disorders

SOUTH SAN FRANCISCO, Calif., July 12, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced the dosing of its first patient in the multi-center Expanded Access Protocol (EAP) for Study of Allogeneic EBV-CTLs in EBV-Associated Lymphomas an...

Glioblastoma Survival Linked to Insurance Status: Oncotherapy Network & Cancer Network

(MedPage Today) -- Also, Epstein-Barr Virus associated with breast cancer risk?

Cognate to make dendritic cell cancer vaccine in $2.2m deal with Astorias

Asterias Biotherapeutics has selected Cognate BioServices for the process development and manufacture of its autologous dendritic cell vaccine candidate, AST-VAC1.

Cognate to make dendritic cell cancer vaccine in $2.2m deal with Asterias

Asterias Biotherapeutics has selected Cognate BioServices for the process development and manufacture of its autologous dendritic cell vaccine candidate, AST-VAC1.

CANCER: Le virus herpès qui prédispose les cellules mammaires à devenir malignes - EBioMedicine

Une nouvelle étude révèle que l'infection par le virus d'Epstein-Barr (VEB), un virus de de la famille des herpès virus humains peut augmenter, chez les femmes, le risque de développer un cancer du sein. Ainsi, les chercheurs de Boston montrent in vitro et in vivo, que l'infection à VEB prédispose les cellules mammaires à devenir malignes. De...

One of the most common viruses in humans may promote breast cancer development

New research reveals that infection with the Epstein-Barr virus (EBV) may put some women at increased risk for developing breast cancer. The findings, published online in the July issue of the journal EBioMedicine, may have important implications for breast cancer screening and prevention.

Three Investigational Vaccine Platforms Induced Immune Responses Against Zika Virus

Three different investigational Zika virus vaccine platforms--an inactivated virus vaccine, a DNA-based vaccine, and an adenovirus vector-based vaccine--protected against infection, induced immune responses, and produced no adverse side effects when tested in rhesus macaques challenged with the Zika virus, according to findings appearing August 4

Scalable Production of Influenza Virus

The future of influenza vaccine production most likely lies with cell culture-based processes. Cell-based systems offer numerous advantages over traditional egg-based production, including speed of production, lack of dependence on egg supply, avoidance of egg allergens, higher initial purity, and ability to combine upstream and downstream into an automated process. Cell culture is well suited...

LabRoots to Host DiaSorin Webinar That Fills in Common Knowledge Gaps About Epstein-Barr Virus Infection

The Webinar will discuss clinical findings and lab tests for diagnosing and staging primary EBV infection, mechanisms by which it causes cancer and autoimmune diseases, and research aimed at preventing it, May 17, 2016 Yorba Linda, CA (PRWEB) April 25, 2016 Despite the fact that infectious mononucleosis has been known as a unique disease for more than 100 years, and that Epstein-Barr virus—whic...

BRIEF-Atara Bio receives ATMP classification for its EBV-CTLs product candidate from EMA

* Atara Bio receives advanced therapy medicinal product classification for allogeneic epstein-barr virus specific cytotoxic T-Lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) Source text for Eikon: Further company coverage: (Bengaluru...

Three vaccine approaches protect monkeys against Zika infection

(NIH/National Institute of Allergy and Infectious Diseases) Three different investigational Zika virus vaccine platforms--an inactivated virus vaccine, a DNA-based vaccine, and an adenovirus vector-based vaccine--protected against infection, induced immune responses, and produced no adverse side effects when tested in rhesus macaques challenged with the Zika virus, according to findings appearing ...

[Articles] Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial

Intradermal zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with subcutaneous zoster vaccine at comparable doses. Larger and longer studies of intradermal administration of live, attenuated zoster vaccine are needed to provide convincing evidence of improved cell mediated immunity.

Sequencing Predicts Cancer Vaccine's Outcomes

Clinical Informatics News | A new study by UCLA researchers demonstrates the use of next generation sequencing to predict survival of brain cancer patients treated with a cancer vaccine. The vaccine, an autologous dendritic cell therapy called DCVax-L, is under development by Northwest Biotherapeutics Inc., of Bethesda, Md., for glioblastoma multiforme (GBM). It is designed to activate the ad...


Quick Search
Advertisement
 

News Quicklinks